Bayer is a global leader in healthcare and offers innovative products that support efforts to overcome challenges presented by a growing and aging global population. Bayer Oncology has developed a therapeutic agent for metastatic advanced prostate cancer, which is approved in more than 50 countries worldwide and is growing its prostate cancer portfolio for the treatment of non-metastatic advanced prostate cancer. Bayer Oncology is also developing medicines to treat patients based on the genomic profile of their tumors, so that the most appropriate treatment option could be selected.  We consistently partner with patient groups, patients and families across design and delivery of our medicines and services to build trust and improve outcomes, experience and access for people impacted by cancer.